UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT


                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934


      Date of Report (Date of earliest event reported): September 15, 2005

                                U.S. MEDSYS CORP.
           -----------------------------------------------------------
             (Exact name of registrant as specified in this charter)


      Colorado                            000-27513             84-1308436
----------------------------         -------------------   ---------------------
(State or other jurisdiction             (Commission          (IRS Employer
    of incorporation)                    File Number)       Identification No.)


     411 Route 17 South, Hasbrouck Heights, New Jersey            07604
    (Address of Principal Executive Offices)                    (Zip Code)


       Registrant's Telephone Number, including area code: (201) 288-3082

                                 NOT APPLICABLE
          (Former Name or Former Address, if Changes Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions.

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))


<PAGE>


Item  7.01. Regulation FD Disclosure.

Attached as an exhibit hereto is a copy of the press release issued by the
Company on September 15, 2005, announcing the matters described below.


Item  8.01. Other Events.

On September 15, 2005, the Company announced that a Search Warrant was issued by
the Magistrate Judge of the U.S. District Court for the District of New Jersey,
together with a subpoena for documents and on September 21, 2005, testimony is
required by its custodian of records before a federal grand jury in Camden, New
Jersey.

The Company has reason to believe that the investigation concerns trading
activity centered on its securities.

During the exercise of the Search Warrant, Special Agents of the Federal Bureau
of Investigation garnered several boxes of Company records, and copied files
from its computers. None of the documents garnered is deemed critical to the
Company's ongoing business operations. As such, the Company will continue to
conduct business in a normal ongoing fashion.

The Company has also learned that other individuals have been served with Search
Warrants and subpoenaed to testify before the grand jury.

Anthony Rubino, acting CEO, commented in the press release, "We have complied
with the order and will provide cooperation as requested. The Company will
continue to focus its efforts on execution of our business model. The last six
months have shown the ability to execute our plan and we are very excited about
our future growth as an organization."

Item  9.01. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits  99.1 Press release dated September 15, 2005.


                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                         U.S. MEDSYS CORP.

                                         By:  /s/ Anthony R. Rubino
                                         ---------------------------------------
                                         Anthony R. Rubino
                                         Acting Chief Executive Officer

Date:  September 23, 2005
{"company-data": {"conformed-name": "US MEDSYS CORP", "cik": "0001095963", "assigned-sic": "5047", "irs-number": "841308436", "state-of-incorporation": "CO", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27513", "film-number": "051099782"}, "business-address": {"street1": "411 ROUTE 17 SOUTH", "city": "HASBROUCK", "state": "NJ", "zip": "07604", "phone": "201-288-3082"}, "mail-address": {"street1": "411 ROUTE 17 SOUTH", "city": "HASBROUCK", "state": "NJ", "zip": "07604"}, "former-company": {"former-conformed-name": "PRIME RATE INCOME & DIVIDEND ENTERPRISES INC", "date-changed": "19990929"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

      Date of Report (Date of earliest event reported): September 15, 2005

                                U.S. MEDSYS CORP.
           -----------------------------------------------------------
             (Exact name of registrant as specified in this charter)

      Colorado                            000-27513             84-1308436
----------------------------         -------------------   ---------------------
(State or other jurisdiction             (Commission          (IRS Employer
    of incorporation)                    File Number)       Identification No.)

     411 Route 17 South, Hasbrouck Heights, New Jersey            07604
    (Address of Principal Executive Offices)                    (Zip Code)

       Registrant's Telephone Number, including area code: (201) 288-3082

                                 NOT APPLICABLE
          (Former Name or Former Address, if Changes Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions.

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))
Item  7.01. Regulation FD Disclosure.

Attached as an exhibit hereto is a copy of the press release issued by the
Company on September 15, 2005, announcing the matters described below.

Item  8.01. Other Events.

On September 15, 2005, the Company announced that a Search Warrant was issued by
the Magistrate Judge of the U.S. District Court for the District of New Jersey,
together with a subpoena for documents and on September 21, 2005, testimony is
required by its custodian of records before a federal grand jury in Camden, New
Jersey.

The Company has reason to believe that the investigation concerns trading
activity centered on its securities.

During the exercise of the Search Warrant, Special Agents of the Federal Bureau
of Investigation garnered several boxes of Company records, and copied files
from its computers. None of the documents garnered is deemed critical to the
Company's ongoing business operations. As such, the Company will continue to
conduct business in a normal ongoing fashion.

The Company has also learned that other individuals have been served with Search
Warrants and subpoenaed to testify before the grand jury.

Anthony Rubino, acting CEO, commented in the press release, "We have complied
with the order and will provide cooperation as requested. The Company will
continue to focus its efforts on execution of our business model. The last six
months have shown the ability to execute our plan and we are very excited about
our future growth as an organization."

Item  9.01. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits  99.1 Press release dated September 15, 2005.

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                         U.S. MEDSYS CORP.

                                         By:  /s/ Anthony R. Rubino
                                         ---------------------------------------
                                         Anthony R. Rubino
                                         Acting Chief Executive Officer

Date:  September 23, 2005